Overview

Duloxetine vs Placebo in the Treatment of General Anxiety

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Duloxetine Hydrochloride